BR0017254A - Treatment and prevention of conditions associated with cardiac insulin resistance - Google Patents

Treatment and prevention of conditions associated with cardiac insulin resistance

Info

Publication number
BR0017254A
BR0017254A BR0017254-5A BR0017254A BR0017254A BR 0017254 A BR0017254 A BR 0017254A BR 0017254 A BR0017254 A BR 0017254A BR 0017254 A BR0017254 A BR 0017254A
Authority
BR
Brazil
Prior art keywords
conditions associated
insulin resistance
treatment
prevention
cardiac
Prior art date
Application number
BR0017254-5A
Other languages
Portuguese (pt)
Inventor
Ameet Nathwani
Original Assignee
Smithkline Beecham Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Plc filed Critical Smithkline Beecham Plc
Publication of BR0017254A publication Critical patent/BR0017254A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

"TRATAMENTO E PREVENçãO DE CONDIçõES ASSOCIADAS à RESISTêNCIA CARDìACA à INSULINA". Trata-se de um método para o tratamento ou profilaxia de resistência cardíaca à insulina ou condições associadas com resistência cardíaca à insulina, em mamíferos humanos ou não humanos, com métodos que compreendem a administração de uma quantidade efetiva, atóxica e farmaceuticamente aceitável de agonista PPARy, tal como Composto (I), ou seu derivado farmaceuticamente aceitável. Condições associadas com resistência cardíaca à insulina são: angina microvascular, aterosclerose e insuficiência cardíaca congestiva. Os compostos incluem rosiglitazona, troglitazona, englitazona e pioglitazona."TREATMENT AND PREVENTION OF CONDITIONS ASSOCIATED WITH INSULIN HEART RESISTANCE". It is a method for the treatment or prophylaxis of cardiac insulin resistance or conditions associated with cardiac insulin resistance in human or non-human mammals, with methods comprising administering an effective, non-toxic and pharmaceutically acceptable amount of PPARγ agonist. , such as Compound (I), or a pharmaceutically acceptable derivative thereof. Conditions associated with cardiac insulin resistance are: microvascular angina, atherosclerosis, and congestive heart failure. The compounds include rosiglitazone, troglitazone, englitazone and pioglitazone.

BR0017254-5A 2000-06-16 2000-06-16 Treatment and prevention of conditions associated with cardiac insulin resistance BR0017254A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/GB2000/002347 WO2001095906A1 (en) 2000-06-16 2000-06-16 Treatment and prevention of cardiac insulin resistance associated conditions

Publications (1)

Publication Number Publication Date
BR0017254A true BR0017254A (en) 2004-01-06

Family

ID=9884792

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0017254-5A BR0017254A (en) 2000-06-16 2000-06-16 Treatment and prevention of conditions associated with cardiac insulin resistance

Country Status (15)

Country Link
EP (1) EP1292301A1 (en)
JP (1) JP2004503499A (en)
CN (1) CN1592620A (en)
AP (1) AP2002002688A0 (en)
BG (1) BG107384A (en)
BR (1) BR0017254A (en)
CA (1) CA2436116A1 (en)
DZ (1) DZ3389A1 (en)
EA (1) EA200300028A1 (en)
HU (1) HUP0301103A2 (en)
IL (1) IL153452A0 (en)
MX (1) MXPA02012619A (en)
NO (1) NO20026000L (en)
WO (1) WO2001095906A1 (en)
YU (1) YU1203A (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7041691B1 (en) 1999-06-30 2006-05-09 Amgen Inc. Compounds for the modulation of PPARγ activity

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9218830D0 (en) * 1992-09-05 1992-10-21 Smithkline Beecham Plc Novel compounds
US5902726A (en) * 1994-12-23 1999-05-11 Glaxo Wellcome Inc. Activators of the nuclear orphan receptor peroxisome proliferator-activated receptor gamma
WO1998005331A2 (en) * 1996-08-02 1998-02-12 Ligand Pharmaceuticals Incorporated Prevention or treatment of type 2 diabetes or cardiovascular disease with ppar modulators
WO1999059586A1 (en) * 1998-05-19 1999-11-25 Regents Of The University Of California Thiazolidine and oxazolidine derivatives for the treatment of acute myocardial infarction and inhibition of cardiomyocyte apoptosis
MA26662A1 (en) * 1998-07-21 2004-12-20 Smithkline Beecham Plc THIAZOLIDINEDIONE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USE

Also Published As

Publication number Publication date
WO2001095906A1 (en) 2001-12-20
NO20026000D0 (en) 2002-12-13
JP2004503499A (en) 2004-02-05
EP1292301A1 (en) 2003-03-19
DZ3389A1 (en) 2001-12-20
IL153452A0 (en) 2003-07-06
NO20026000L (en) 2003-02-11
EA200300028A1 (en) 2003-04-24
BG107384A (en) 2003-09-30
MXPA02012619A (en) 2003-04-10
YU1203A (en) 2006-05-25
HUP0301103A2 (en) 2003-08-28
CA2436116A1 (en) 2001-12-20
AP2002002688A0 (en) 2002-12-31
CN1592620A (en) 2005-03-09

Similar Documents

Publication Publication Date Title
RU2252032C2 (en) New field of compound application as antimictobial agents
BRPI0408784A (en) method to use a compound
BR0313743A (en) Benzimidazole quinolinones and uses of these
DOP2004001052A (en) 11-BETA-HYDROXIESTEROID DEHYDROGENASE TYPE 1 INHIBITORS AMINO
WO1998005331A3 (en) Prevention or treatment of type 2 diabetes or cardiovascular disease with ppar modulators
LU91935I2 (en) Tafamidis and its pharmaceutically acceptable salts, including tafamidis meglumine salt (VYNDAQEL®)
NO20075042L (en) Pharmaceutical composition including an omega-carboxyaryl-substituted diphenylurea for the treatment of cancer
NO20090595L (en) New pyridazine compound and its use
CO5700796A2 (en) COMPOSITIONS CONTAINING PIPERACILIN AND TAZOBACTAM USEFUL FOR INJECTIONS
TW200420549A (en) Thiazole derivatives
BR0213522B8 (en) hydroxypyrimidinone derivative compounds, pharmaceutical composition, and use of a compound
WO2007130075A8 (en) Aminothiazole derivatives as human stearoyl-coa desaturase inhibitors
NO331021B1 (en) Medication for the treatment of cancer comprising quinolone derivatives in combination with 5-FU or CPT-11 and use of the derivatives
BR9911498A (en) Compound, pharmaceutical composition, use of a compound, and, process to treat a patient suffering from a condition where there is a benefit in reducing the plasma-free fatty acid concentration or reducing the heart rate
BR0112476A (en) Use of dopamine d2 / d3 receptor agonists to treat fibromyalgia
NO20083004L (en) Use of benzofused heterocyclic sulfamide derivatives for the treatment of drug addiction
BRPI0517650A (en) use of ranolazine in combination with at least one remodeling agent for reversal of left ventricular remodeling in the treatment of heart failure.
AR119158A1 (en) HEREDITARY ANGIOEDEMA TREATMENTS
NO20054216L (en) Use of dipyridamole in combination with acetylsalicylic acid and an angiotensin II antagonist for stroke prevention
AU2009246603A8 (en) Von willebrand factor (vwf) inhibitors for treatment or prevention of infarction
MX2020001342A (en) Use of gaboxadol in the treatment of diabetes and related conditions.
BR0107628A (en) 1,2-diarylbenzimidazoles for treating diseases that are associated with microglial activation
BR0017254A (en) Treatment and prevention of conditions associated with cardiac insulin resistance
MX9805512A (en) Treatment and prevention of cardiac insulin resistance associated conditions.
CO4940489A1 (en) NEW METHOD OF TREATMENT CINEMA ASSOCIATED WITH THE SAME IN MAMMALS

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 3A,6A,7A E 8A ANUIDADE

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO PUBLICADO NA RPI 1942 DE 25 - 03 - 2008.